Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by CarbonWarrioron Nov 23, 2022 12:16pm

204 Views

Post# 35122297

RE:RE:RE:RE:RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

I listened to conf call of August 11 2022.

They said they will not release anything until - major cancer conference in 2023 so be more material/relevent.
Never seen this before.
They also said they know the results of bracelet in real time, so they would know now if it is a failure.

I still think that if results are awful, they would need to disclose to market based on materiality rules.

So, no news is good news.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta